Suppr超能文献

致糖尿病性CD8 + T细胞的基因与治疗性控制

Genetic and therapeutic control of diabetogenic CD8+ T cells.

作者信息

Santamaria Pere

机构信息

Julia McFarlane Diabetes Research Centre (JMDRC) and Department of Microbiology and Infectious Diseases, Institute of Inflammation, Infection and Immunity, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada.

出版信息

Novartis Found Symp. 2008;292:130-6; discussion 136-45, 202-3. doi: 10.1002/9780470697405.ch12.

Abstract

CD8+ T cells are important contributors to the initiation and progression of type 1 diabetes (T1D). A very significant fraction of islet-associated CD8 T cells in NOD mice recognize epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), a non-essential endoplasmic reticulum-resident protein of unclear function. IGRP is also a target of CD8 T cell responses in human T1D patients. In NOD mice, most IGRP-reactive CD8 T cells target the IGRP(206-214) epitope and are diabetogenic. We have shown that the pathogenic activity of this T cell subset is controlled by genetic elements associated with diabetes susceptibility and resistance. One of these elements (Il2) has been recently implicated in susceptibility to several human autoimmune disorders, including TID. In mice, Il2 polymorphisms control a negative feedback mechanism initiated by activated, IL2-producing autoreactive T cells in the pancreatic lymph nodes that increases the regulatory activity of CD4+CD25+ T cells. Not all IGRP-reactive CD8 T cell clones are pathogenic, however, and we have evidence that some of these clonotypes are actually anti-diabetogenic. We had previously shown that administration of altered peptide ligands (APL) targeting IGRP(206-214)-reactive CD8 T cells resulted in diabetes protection only at doses that did not delete low-avidity clones, suggesting a protective role for these clonotypes. I discuss evidence showing that transgenic expression of a low-avidity IGRP(206-214)-reactive T cell receptor (TCR) efficiently prevents the development of insulitis and diabetes in NOD (non-obese diabetic) mice and that these cells do so by killing autoantigen-loaded antigen presenting cells in the pancreas-draining lymph nodes. These results illustrate a novel mechanism for regulation of immune responses to self-antigens and expose a new target for therapeutic intervention. Here I briefly summarize work done by us and others indicating that a prevalent subset of autoreactive CD8 T-cells in the NOD mouse are major (albeit likely dispensable) players in the pathogenesis of spontaneous autoimmune diabetes in the NOD mouse; that these T cells are targets of genetic elements affording autoimmune disease susceptibility and resistance; that they can either be diabetogenic or anti-diabetogenic according to their avidity for peptide/MHC; and that they can serve as useful targets for therapeutic intervention.

摘要

CD8+ T细胞在1型糖尿病(T1D)的发生和发展中起着重要作用。在非肥胖糖尿病(NOD)小鼠中,很大一部分胰岛相关CD8 T细胞识别胰岛特异性葡萄糖-6-磷酸酶催化亚基相关蛋白(IGRP)的表位,IGRP是一种功能不明的非必需内质网驻留蛋白。IGRP也是人类T1D患者CD8 T细胞反应的靶点。在NOD小鼠中,大多数对IGRP有反应的CD8 T细胞靶向IGRP(206 - 214)表位并且具有致糖尿病作用。我们已经表明,这个T细胞亚群的致病活性受与糖尿病易感性和抗性相关的遗传因素控制。其中一个因素(Il2)最近被认为与包括TID在内的几种人类自身免疫性疾病的易感性有关。在小鼠中,Il2多态性控制着一种负反馈机制,该机制由胰腺淋巴结中活化的、产生IL2的自身反应性T细胞启动,可增强CD4+CD25+ T细胞的调节活性。然而,并非所有对IGRP有反应的CD8 T细胞克隆都具有致病性,我们有证据表明其中一些克隆型实际上具有抗糖尿病作用。我们之前已经表明,给予靶向对IGRP(206 - 214)有反应的CD8 T细胞的改变肽配体(APL)仅在不清除低亲和力克隆的剂量下才会导致糖尿病得到保护,这表明这些克隆型具有保护作用。我讨论了相关证据,这些证据表明低亲和力的对IGRP(206 - 214)有反应的T细胞受体(TCR)的转基因表达能有效预防NOD(非肥胖糖尿病)小鼠发生胰岛炎和糖尿病,并且这些细胞通过杀死胰腺引流淋巴结中负载自身抗原的抗原呈递细胞来实现这一点。这些结果阐明了一种调节对自身抗原免疫反应的新机制,并揭示了一个新的治疗干预靶点。在此,我简要总结我们和其他人所做的工作,这些工作表明NOD小鼠中普遍存在的自身反应性CD8 T细胞亚群是NOD小鼠自发性自身免疫性糖尿病发病机制中的主要(尽管可能并非必不可少)参与者;这些T细胞是赋予自身免疫性疾病易感性和抗性的遗传因素的靶点;它们根据对肽/MHC的亲和力不同,既可以是致糖尿病的,也可以是抗糖尿病的;并且它们可以作为治疗干预的有用靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验